top glp-1 medications for weight loss 2025 Dozens of new obesity drugs are coming: these are the ones to watch Poll: 1 in 8 Adults

Book an Appointment Get guidance based on your health history, lab results, medications, and long-term goals

The HRs comparing tirzepatide versus controls were 0.80 (0.571.11) for MACE-4

Incidence Rates and Clinical Trial Data on GLP-1Associated Headaches Major clinical trials for semaglutide, tirzepatide, and other GLP-1 agonists document headache occurrence across different patient populations, doses, and indications

Most common side effects were gastrointestinal, with 24.5% of participants in the phase 2 obesity trial discontinuing efinopegdutide 10 mg due to AE however when the same dose was used with gradual escalation at the MASLD trial (starting dose 2.4 mg for 4 weeks, then 5 mg for 4 weeks and then 10 mg), only 5.6% of participants discontinued the medication due to AE

Lorcaserin, 25%

However, these agents were linked to an increased likelihood of procedure discontinuation, presumably due to aggravated gastric retention [22]